The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...

Leinco Technologies offers high-purity research-grade biosimilar antibodies with the same specifications as many therapeutic antibodies. Therapeutic antibodies are widely used for the treatment of ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

PALO ALTO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Bioz, Inc. is setting the standard for AI-powered research ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Type I allergy, an IgE antibody triggered hypersensitivity disease, represents a common public health problem affecting about one third of the world´s population. Upon exposure to allergens, IgE ...

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine, a ...

a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug, ...

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...